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The data presented in this article are related to the research
article entitled Hemopexin counteracts systolic dysfunction
induced by heme-driven oxidative stress (G. Ingoglia, C. M. Sag,
N. Rex, L. De Franceschi, F. Vinchi, J. Cimino, S. Petrillo, S. Wagner,
K. Kreitmeier, L. Silengo, F. Altruda, L. S. Maier, E. Hirsch, A. Ghigo
and E. Tolosano, 2017) [1]. Data show that heme induces reactive
oxygen species (ROS) production in primary cardiomyocytes.
H9c2 myoblastic cells treated with heme bound to human
Hemopexin (Hx) are protected from heme accumulation and
oxidative stress. Similarly, the heme-driven oxidative response is
reduced in primary cardiomyocytes treated with Hx-heme com-
pared to heme alone. Our in vivo data show that mouse models of
hemolytic disorders, β-thalassemic mice and phenylhydrazine-
treated mice, have low serum Hx associated to enhanced
expression of heme- and oxidative stress responsive genes in the
heart. Hx-/- mice do not show signs of heart ﬁbrosis or overtvier Inc. This is an open access article under the CC BY license
/j.freeradbiomed.2017.04.003
Tolosano).
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G. Ingoglia et al. / Data in Brief 13 (2017) 69–7670inﬂammation. For interpretation and discussion of these data,
refer to the research article referenced above.
& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Health sciences
ore speciﬁc
subject areaHeme/iron biologyype of data Text ﬁle, Figures
ow data was
acquiredOlympus BH-2 microscope (Olympus Italia, Milan, Italy), 7300 Real Time PCR
System (Applied Biosystems, Life Technologies Italia), spectroﬂuorimeter
(Glomax, Promega Italia)ata format Raw, analyzed
xperimental
factorsH9c2 (ATCC CRL-1446™) myoblast cell line; mouse neonatal primary cardio-
myocytes; Hx-/- mice; β-thalassemia mice; C57BL/6 wild-type micexperimental
featuresGene expression was analyzed by qRT-PCR and Western blotting. Tissue
inﬂammation was analyzed by histology and immunohistochemistry. Heme
content and ROS accumulation were quantiﬁed by ﬂuorometric methods.ata source
locationDept. Molecular Biotechnology and Health Sciences, Torino, Italyata accessibility The data are available with this article.DValue of the data
 These data show that the plasma protein hemopexin (Hx) limits heme accumulation within cardiac
cells both in vitro and in vivo
 In mice, heme-driven oxidative stress associated to Hx exhaustion can be recovered by the
administration of the anti-oxidant α-tocopherol
 These ﬁnding might be exploited in the future for the development of Hx-based drugs able to
prevent cardiac heme accumulation and oxidative stress in hemolytic disorders and/or in
pathologic conditions associated with heme overload1. Data
Data show that heme induced ROS production in primary cardiomyocytes (Fig. 1). Hx limited heme
accumulation within H9c2 cell (myoblast cell line) and prevented ROS production. H9c2 cells were
treated with heme alone or heme bound to Hx,and heme content, ROS production, the expression of
heme- and oxidative stress responsive genes and markers of oxidative stress were evaluated (Fig. 2).
These data were conﬁrmed in primary cardiomyocytes isolated from neonatal mice and treated with
either heme alone or heme-Hx (Fig. 3) and, indirectly in the heart of Hx-/- mice (Fig. 4). Data in Fig. 5
show that the heart of Hx-/- mice, despite of heme accumulation and elevated ROS [1], did not show
sign of ﬁbrosis and inﬂammation apart a slight increase in the level of Tumor Necrosis Factor (TNF)α
and Interleukin (IL)-6 mRNAs.
In vivo, Hx depletion in mouse models of hemolytic disorders, β-thalassemic mice and phe-
nylhydrazine (PHZ)-treated mice, was associated with heme accumulation and oxidative stress in the
Fig. 1. Heme promotes ROS formation in isolated adult rat cardiomyocytes. Data on isolated adult rat cardiomyocytes exposed
to heme (5 mM) or vehicle (not-treated, Nt) are shown. ROS were measured by using the ﬂuorescent dye CM-H2DCFDA
(Nt, n ¼ 22; heme, n ¼ 17). Two-way ANOVA with Bonferroni post-test analysis was performed. *P o 0.05; #P o 0.05 (#,
difference between Nt and heme-treated cells; *, difference between time 0 and time 11 in Nt and heme-treated cells).
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expression of heme- and oxidative stress responsive genes in the heart (Fig. 6). The same occurred in
PHZ-treated mice (Fig. 7). Administration of the anti-oxidant α-tocopherol to PHZ-treated mice
normalized the expression of anti-oxidant genes (Fig. 8).2. Experimental Design, Materials and Methods
2.1. Cells and treatments
H9c2 (ATCC CRL-1446™) cells and primary cardiomyocytes, isolated from neonatal mice were
treated with either 10 mM Hx-heme complex or 10 mM heme for 8 hours. Primary adult rat cardio-
myocytes were treated with 5 mM heme or vehicle for 15 min. Heme and Hx-heme complex were
prepared as described [1].2.2. Mice and treatments
Hx-/- mice and β-thalassemia mice were previously generated [2–7]. C57BL/6 wild-type mice were
administered intraperitoneally (i.p.) with 25 mg/kg phenylhydrazine (PHZ, Sigma-Aldrich, Saint Luis,
USA) twice a week for 4 weeks. PHZ-treated mice were injected i.p. with 400 mg/kg α-tocopherol
(Sigma-Aldrich) dissolved in corn oil or with vehicle on the day of PHZ injection.2.3. Gene expression analysis
Total RNA, from cells or tissues, was extracted using Pure Link RNA Mini Kit (Ambion, Life Tech-
nologies Italia, Milano, Italy). qRT-PCR was performed on a 7300 Real Time PCR System (Applied
Biosystems, Life Technologies Italia). Primers and probes were designed using the ProbeFinder soft-
ware (http://www.roche-applied-science.com).
For Western blotting, tissue and cell proteins were extracted as reported [1]. Fifty mg total protein
or 0.25 mL mouse serum were separated on SDS-PAGE and immunoblotted using antibodies against
HO-1 (dilution 1:300, Enzo Life Sciences), Hx (1:1000) [8], N-Tyr (1:1000, Merck Millipore).
Fig. 2. Hemopexin protects H9c2 cells from heme accumulation and ROS production. Data on H9c2 myoblasts cell line
untreated (NT) or treated with either 10 mM Hx-heme complex or 10 mM heme for 8 hours, are shown. (A) Heme content.
(B) qRT-PCR analysis of Ho-1 mRNA levels. (C) Western blot analysis of HO-1. (D) ROS content and (E) qRT-PCR analysis
of γ-Glutamylcysteine synthetase (γ-Gcs) and Thioredoxin mRNA levels. (F) Western blot analysis of N-Tyr.
(G) Immunoﬂuorescence analysis of super-oxide radical formation (super-oxide radical was stained with Mito-sox ﬂuorescent
probe. Nuclei were stained with DAPI). Results shown are representative of three independent experiments. One-way analysis
of variance with Bonferroni post-test analysis was performed. *P o 0.05; **P o 0.01; ***P o 0.001. Values represent mean 7
SEM. AU, arbitrary units; RQ, relative quantity; FIU, ﬂuorescence intensity unit.
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Fig. 4. Hemopexin preserves heme homeostasis in the heart. Data on the heart of wild-type (Wt) and Hx-/- mice are shown.
(A) qRT-PCR analysis of Flvcr1a, Fpn, Dmt1 and Tfr1 mRNA levels. (B) Western blot analysis of Tfr1 protein. Results shown are
representative of 3 independent experiments. In B, each lane represents an individual animal; E-cadherin (E-Cad) was used as
loading control. Unpaired t-test analysis with Welch's correction was performed. Values represent mean 7 SEM. *Po0.05.
Fig. 3. Hemopexin protects neonatal cardiomyocytes and H9c2 cells from heme accumulation and ROS formation. Data on
neonatal cardiomyocytes and H9c2 cells untreated (NT) or treated with either 10 mM Hx-heme complex or 10 mM heme for
8 hours, are shown. (A, C) qRT-PCR analysis of Fpn, Tfr1, γ-Gcs and Thioredoxin reductase mRNA levels of neonatal cardio-
myocytes. (B) qRT-PCR analysis of Flvcr1a mRNA levels of H9c2 cells. One-way analysis of variance with Bonferroni post-test
analysis was performed. *P o 0.05; **P o 0.01; ***P o 0.001.
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Heme content in cells and tissues was quantiﬁed ﬂuorometrically by the method of Sassa [9,10].
Accumulation of ROS in heart homogenates or cells was assessed by using either 29,79-dichlor-
odihydroﬂuoroscein diacetate (H2DCFDA; Molecular Probes, Inc., Eugene, OR) [11] or MitoSOX
(ThermoFisher Scientiﬁc, Waltham, MA USA).
Fig. 5. Hemopexin loss is not associated with heart ﬁbrosis. Data on Wt and Hx-/- mice are shown. (A) Representative Picro-
sirius Red staining of heart sections from a Wt and an Hx-/- mouse. ImageJ analysis of Picrosirius Red stained sections is shown
on the right. (B) Immunohistochemistry analysis of CD18 expression on heart sections of a Wt and a Hx-/- mouse. (C) qRT-PCR
analysis of collagen type I and III, Tnf-α and IL6 mRNA levels in the heart (n ¼ 5). Unpaired t-test analysis with Welch's
correction was performed. Values represent mean 7 SEM. *Po0.05.
Fig. 6. β-thalassemic mice are hemolytic and accumulate heme in the heart. Data on Wt and β-thalassemic (β-Thal) mice are
shown. (A) ELISA quantiﬁcation of serum Hx. (B) qRT-PCR analysis of Ho-1, Fpn and γ-Gcs mRNA levels in the heart. (C) HO-1
western blot analysis. Unpaired t-test analysis with Welch's correction was performed. nP o 0.05; nnnP o 0.001. Values
represent mean 7 SEM.
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Fig. 7. PHZ-treated mice show an alteration of heme- and oxidative stress-responsive genes in the heart. (A) Western blot of
serum Hx of untreated (0) or PHZ-treated Wt mice at 1, 2 or 4 weeks of treatment. (B) qRT-PCR analysis of Ho-1, Flvcr1a, Fpn,
Gsr, mRNA levels in the heart of untreated or PHZ-injected mice after 4 weeks of treatment. In A, one-way ANOVA with
Bonferroni post-test analysis was performed; in B, unpaired t-test analysis with Welch's correction was performed. *P o 0.05;
** P o 0.01; ***P o 0.001.
Fig. 8. α-tocopherol protects the heart against PHZ-mediated oxidative stress. Data on the heart of PHZ-treated Wt mice
administered or not with α-tocopherol are shown. (A) qRT-PCR analysis of γ-Gcs and peroxiredoxin 6 (Prdx6) mRNA levels of
PHZ- and PHZ-α-tocopherol-treated mice (n¼7) 4 weeks after the treatment. One-way analysis of variance with Bonferroni
post-test analysis were performed. nP o 0.05; nnnP o 0.001. Values represent mean 7 SEM. RQ, relative quantity.
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Hearts were processed as described and analyzed by immunohistochemistry with an anti- CD18
antibody (1:100, Biolegend). For collagen quantiﬁcation, tissue sections were stained with Picrosirius
Red and analyzed by Image J program.
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Results were expressed as mean 7 SEM. Comparisons between 2 groups were performed with 2-
sided Welch t tests and among 42 groups with 1- or 2-way ANOVA followed by the Bonferroni post-
test (GraphPad software Inc, La Jolla, CA). A value of Po0.05 was considered signiﬁcant.Acknowledgements
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